Startups
Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. The company is founded on the belief that the repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one
of the greatest opportunities for innovation in medical science. Repertoire scientists created and developed the DECODE and DEPLOY suite of technologies, which allow in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines.
From its sites in Cambridge, Mass., and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform. The company’s first product in the clinic is a novel multiclonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens and armed with a proprietary cytokine payload. Repertoire is in clinical-stage immuno-oncology development today, targeting metastatic solid tumors. In the field of autoimmunity, Repertoire is using its proprietary platform to discover novel epitopes and TCRs from patients with type 1 diabetes. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones.
To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.
of the greatest opportunities for innovation in medical science. Repertoire scientists created and developed the DECODE and DEPLOY suite of technologies, which allow in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines.
From its sites in Cambridge, Mass., and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform. The company’s first product in the clinic is a novel multiclonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens and armed with a proprietary cytokine payload. Repertoire is in clinical-stage immuno-oncology development today, targeting metastatic solid tumors. In the field of autoimmunity, Repertoire is using its proprietary platform to discover novel epitopes and TCRs from patients with type 1 diabetes. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones.
To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.
Overview
Location
United States, Massachusetts, Cambridge
Employees
51-200
Total raised
$189M
Founded date
2020
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 13, 2021 | Repertoire Immune Medicines : Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets | Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the completion of a $18... |
| Mar 25, 2020 | Repertoire Immune Medicines Raises Investment from JDRF T1D Fund | Repertoire Immune Medicines, a newly launched company working to surface the power of the immune system to prevent and cure disease, received an investment from the JDRF T1D Fund. The amount of the deal was not disclosed. The company intend... |
| Mar 13, 2020 | Flagship combines two startups into cell therapy-focused Repertoire Immune Medicines | Torque and Cogen have raised a combined $220 million to date. In an emailed statement, Flagship noted that the majority of that funding was raised last year, led by Flagship and with several additional private investment groups participatin... |
| Flagship combines two startups into cell therapy-focused Repertoire Immune Medicines | A life sciences investment firm is combining two of its portfolio companies into a single entity that it said would focus on using immunotherapy to treat cancers, autoimmune and infectious diseases. Cambridge, Massachusetts-based Flagship P... |
Reviews 0
FAQ about Repertoire Immune Medicines
When was Repertoire Immune Medicines founded?
Repertoire Immune Medicines was founded in 2020.
How much funding has Repertoire Immune Medicines raised?
Repertoire Immune Medicines has raised $189M in total across 1 funding round.
What has the press written about Repertoire Immune Medicines?
Parsers VC has collected 5 articles mentioning Repertoire Immune Medicines, among them “Repertoire Immune Medicines : Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets” (Apr 13, 2021) and “Repertoire Immune Medicines Raises Investment from JDRF T1D Fund” (Mar 25, 2020).
Is Repertoire Immune Medicines still active?
Yes, Repertoire Immune Medicines is active; its latest activity on Parsers VC dates from Apr 13, 2021.